je.st
news
Tag: trials
UK Royal Navys Merlin Mk3 helicopter undergoes sea trials
2015-03-31 01:00:00| Naval Technology
The UK Royal Navy's (RN) Green Merlin Mk 3 helicopter has started sea trials onboard the Royal Fleet Auxiliary (RFA) Lyme Bay.
Tags: sea
royal
trials
helicopter
Upgraded HMS Sutherland sails for sea trials
2015-03-30 01:00:00| Naval Technology
The UK Royal Navy's Type 23 frigate HMS Sutherland has set sail for sea trials, after the completion of upgrade and substantial maintenance programme at Babcock's Devonport Royal Dockyard.
Tags: sea
trials
upgraded
sutherland
USNS Trenton JHSV 5 completes US Navy acceptance trials
2015-03-26 01:00:00| Naval Technology
The US Navy's new joint high-speed vessel 5 (JHSV 5), USNS Trenton, has successfully completed acceptance trials in the Gulf of Mexico, marking a major milestone prior to its delivery.
Tags: acceptance
navy
trials
completes
Upgraded Arleigh Burke-class USS Curtis Wilbur destroyer completes sea trials
2015-03-19 01:00:00| Naval Technology
The US Navys Arleigh Burke-class guided-missile destroyer USS Curtis Wilbur (DDG 54) has completed sea trials following a DDG midlife overhaul extended dry dock shipboard repair availability (EDSRA).
Tags: sea
trials
upgraded
curtis
New Data Investigating Mercks KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
2015-03-18 21:19:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Data to be Presented Across Multiple Tumor Types for KEYTRUDA and MK-8628 (OTX015), an Investigational BET-Bromodomain Inhibitor KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in both advanced non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma will be presented as part of the Clinical Trials Plenary Session on Sunday, April 19 at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, April 18 22. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
presented
cell
Sites : [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] next »